An isopentenylphenolic compound, its preparation method and application
By extracting and purifying isopentenylphenolic compound I from the stems and branches of black mulberry, the problem of limited drug variety and significant side effects has been solved. This method achieves high affinity for PPARγ to reduce insulin resistance and increase adiponectin levels, with minimal side effects.
Patent Information
- Application Number
- CN202211407242.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-10
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-11-10
AI Technical Summary
There are few existing drugs for reducing insulin resistance, and they have side effects, such as weight gain, water and sodium retention, osteoporosis, and cardiovascular risks caused by rosiglitazone.
A pharmaceutically acceptable salt of isopentenylphenolic compound I or thereof is provided, which is obtained by extraction from black mulberry stems and branches and purification by multi-step column chromatography and HPLC. It has a strong affinity for PPARγ, can reduce glucose content in the cell sap of insulin resistance model cells and increase adiponectin levels, and has few side effects.
Isoprene phenolic compound I significantly reduced glucose levels and increased adiponectin levels in insulin-resistant model cells, without significantly promoting adipocyte differentiation, and had few side effects.
Smart Images

Figure CN118047788B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to an isopentenylphenolic compound, its preparation method, and its application. Background Technology
[0002] With the improvement of living standards and changes in lifestyle, the number of people with type 2 diabetes is constantly increasing, seriously affecting people's health and quality of life. Insulin resistance (IR) is one of the main causes of type 2 diabetes. It is mainly manifested as decreased sensitivity of peripheral tissues such as the liver and adipose tissue to insulin, leading the body to compensate by producing more insulin to maintain blood glucose levels, resulting in hyperinsulinemia, which further leads to glucose and lipid metabolism disorders, thus causing metabolic diseases such as type 2 diabetes. Rosiglitazone, as a drug for treating diabetes, can improve IR resistance and increase insulin sensitivity, but it also brings many adverse reactions, such as weight gain, water and sodium retention, osteoporosis, tumors, and cardiovascular risks. Therefore, the discovery of highly effective and safe insulin sensitizers is of great value.
[0003] Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear receptor transcription factor mainly expressed in adipose tissue, playing a key role in adipocyte differentiation and glucose-lipid metabolism homeostasis. PPARγ binds to its ligand, activating the transcription of the PPARγ receptor gene, further increasing the expression of adipogenesis-related factors (C / EBPα, aP2, FAS, etc.), thereby promoting adipocyte differentiation. It also upregulates the expression of the insulin-sensitizing factor adiponectin, increasing glucose transport in peripheral tissues, thus improving insulin resistance and exerting a hypoglycemic effect. PPARγ is an important target for the discovery of insulin sensitizers. Simultaneously, PPARγ is also closely related to diseases such as obesity, hypertension, atherosclerosis, and tumors, and PPARγ ligands have shown beneficial effects on all of these diseases (Research Progress on the Relationship between PPARγ Function and Disease. Chinese Journal of Pharmacology, 2012, 28(5):601-4).
[0004] Black mulberry (Morus nigra L.) is a plant belonging to the genus Morus in the family Moraceae. As a traditional Chinese medicine, it has effects such as lowering blood sugar, blood lipids, and blood pressure, and antiviral activity. Related research reports have found that black mulberry leaves and stems contain abundant active substances, such as phenolic components, including flavonoids, stilbenesides, and DA adducts; alkaloids; and coumarins. Among these, water-soluble and phenolic components have a hypoglycemic effect. Currently, water-soluble alkaloids have been developed into mulberry twig total alkaloid tablets for the market. Summary of the Invention
[0005] The technical problem this invention aims to solve is the limited variety of existing drugs for reducing insulin resistance. Therefore, this invention provides an isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof. This isopentenylphenolic compound has a strong affinity for PPARγ, significantly reducing glucose levels in the cellular fluid of insulin-resistant models and increasing adiponectin levels; simultaneously, it exhibits weak agonistic activity towards PPARγ, with no significant adipocyte differentiation-promoting effect and minimal side effects.
[0006] The present invention solves the above-mentioned technical problems through the following technical solutions.
[0007] This invention provides an isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof.
[0008]
[0009] In one embodiment of the present invention, the isopentenylphenolic compound I may be:
[0010]
[0011] In one embodiment of the present invention, the retention time of the isopentenylphenolic compound I under the following HPLC conditions is 23.7 min:
[0012] Column type: Agilent Eclipse XDB-C 18 (250×10mm, 5μm)
[0013] Mobile phase and its volume ratio: Acetonitrile:water = 63:37
[0014] Injection volume: 200 μL
[0015] Column temperature: room temperature,
[0016] Detection wavelength: 210nm
[0017] Flow rate: 3 mL / min.
[0018] In one embodiment of the present invention, the retention time of the isopentenylphenolic compound I under the following HPLC conditions is 23.7 min:
[0019] Column type: Agilent Eclipse XDB-C 18 (250×10mm, 5μm)
[0020] Mobile phase and its volume ratio: Acetonitrile:water = 63:37
[0021] Injection volume: 200 μL
[0022] Column temperature: room temperature,
[0023] Detection wavelength: 210nm
[0024] Flow rate: 3 mL / min
[0025] Preparative liquid chromatography: LC3050N high performance liquid chromatograph.
[0026] The present invention also provides a method for preparing the above-mentioned isopentenylphenolic compound I, which includes the following steps:
[0027] ① The ethanol extract of black mulberry stems and branches was suspended in water and subjected to AB-8 macroporous resin column chromatography. The eluent was eluted with water, 40% ethanol and 95% ethanol respectively. The eluent obtained by elution with 95% ethanol was concentrated and dried to obtain mixture 1.
[0028] ② The mixture 1 was subjected to silica gel column chromatography with gradient elution using a mixed solution of petroleum ether and ethyl acetate. The volume ratios of petroleum ether and ethyl acetate were 10:1, 7:1, 5:1, 2:1, 1:1, and 2:3, respectively. The eluent, which was analyzed by silica gel thin-layer chromatography and showed a dichloromethane and methanol volume ratio of 12:1 with an Rf value of 0.40, was collected, concentrated, and dried to obtain mixture 2.
[0029] ③ The mixture 2 was subjected to gel column chromatography and eluted with dichloromethane and methanol in a volume ratio of 1:1. The eluent was collected and analyzed by silica gel thin-layer chromatography. The eluent had a dichloromethane and methanol volume ratio of 12:1 and an Rf value of 0.40. The mixture 3 was obtained by concentration and drying.
[0030] ④ The mixture 3 was subjected to reversed-phase silica gel column chromatography with gradient elution of methanol and water. The volume ratio of methanol to water was 40:60, 50:50, 60:40, 70:30, 80:20, and 90:10, respectively. The eluent was collected and analyzed by silica gel thin-layer chromatography. When the volume ratio of dichloromethane to methanol was 12:1, the Rf value was 0.40. After concentration, the crude product of isopentenylphenolic compound I was obtained.
[0031] ⑤ The crude isopentenylphenolic compound I was purified by HPLC. The stationary phase of the HPLC column was C18 bonded silica gel, and the mobile phase was a mixed solution of acetonitrile and water; the volume ratio of acetonitrile to water was 63:37.
[0032] The preparation method may further include the following steps;
[0033] The coarse powder of black mulberry stems and branches was extracted with ethanol, and the extract was filtered and concentrated to obtain the ethanol extract of black mulberry stems and branches.
[0034] In one aspect of the present invention, during the extraction of the coarse powder from black mulberry stems and branches with ethanol, the ethanol is 85% to 95% ethanol, for example, 90% ethanol.
[0035] In one aspect of the present invention, during the extraction of the coarse powder from black mulberry stems and branches with ethanol, the extraction temperature is 75–90°C, for example, 80°C.
[0036] In one aspect of the present invention, during the extraction of the coarse powder from black mulberry stems and branches with ethanol, the volume-to-mass ratio of ethanol to the coarse powder from black mulberry stems and branches is 5-10 L / kg, for example, 8 L / kg.
[0037] In one aspect of the present invention, during the extraction of the coarse powder from black mulberry stems and branches with ethanol, the extraction is performed 1 to 3 times, for example, 2 times.
[0038] In one aspect of the present invention, during the extraction of the coarse powder from black mulberry stems and branches with ethanol, the extraction time is 0.5 to 2 hours, for example, 1 hour.
[0039] In one aspect of the present invention, in step ①, when the ethanol extract is suspended in water, the weight ratio of the ethanol extract to the water is 1:5 to 15, for example, 1:10.
[0040] In one embodiment of the present invention, in step ①, when performing AB-8 macroporous resin column chromatography, the amounts of water, 40% ethanol, and 95% ethanol are 5 times the column volume, respectively.
[0041] In one embodiment of the present invention, in step ②, the amount of the petroleum ether and ethyl acetate mixed solution used in each gradient is 3 times the column volume.
[0042] In one embodiment of the present invention, in step ③, the filler of the gel column is hydroxypropyl dextran gel, preferably LH-20.
[0043] In one embodiment of the present invention, in step ④, the packing material for the reversed-phase silica gel column chromatography is preferably ODS-C18, and more preferably ODS-A-HG.
[0044] In one embodiment of the present invention, in step ④, when performing gradient elution with methanol and water, the amount of mixed solvent used for each gradient is 3 times the column volume.
[0045] In one embodiment of the present invention, in step ⑤, the particle size of the packing material of the HPLC column is 5-10 μm, for example, 5 μm.
[0046] In one embodiment of the present invention, in step ⑤, the length of the HPLC column is 100-250 mm, for example, 250 mm.
[0047] In one embodiment of the present invention, in step ⑤, the inner diameter of the HPLC column is 9.4 to 30 mm, for example, 10 mm.
[0048] In one embodiment of the present invention, in step ⑤, the HPLC column is an Agilent Eclipse XDB-C. 18 ,250×10mm,5μm.
[0049] In one embodiment of the present invention, in step ⑤, the column temperature of the HPLC column is 20–50°C, for example, room temperature.
[0050] In one aspect of the present invention, in step ⑤, the detection wavelength of the HPLC is 200-400 nm, for example 210 nm.
[0051] In one embodiment of the present invention, in step ⑤, the flow rate of the mobile phase of the HPLC is 1 to 15 mL / min, for example 3 mL / min.
[0052] In one embodiment of the present invention, in step ⑤, the injection volume of the HPLC is 10 to 1000 μL, for example, 200 μL.
[0053] The present invention also provides a pharmaceutical composition comprising: the isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient.
[0054] In the pharmaceutical composition described herein, the isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof may be the sole active ingredient.
[0055] In the pharmaceutical composition, the pharmaceutical excipients are those conventionally applicable in the art, preferably sucrose, gelatin, glycerin, pregelatinized starch, microcrystalline cellulose, lactose, or inorganic calcium salts.
[0056] The pharmaceutical composition may be in the form of tablets, capsules, granules, powders, or liquid preparations.
[0057] The pharmaceutical composition may be administered to the subject by any suitable route, preferably orally, intravenously or topically, and more preferably orally.
[0058] The pharmaceutical composition described herein may be prepared using methods known to those skilled in the art.
[0059] The present invention also provides the use of the isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof in the preparation of an insulin sensitizer.
[0060] The present invention also provides the use of the isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof in the preparation of a PPARγ partial agonist.
[0061] The present invention also provides the use of the isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the prevention or treatment of insulin resistance or metabolic diseases thereof.
[0062] The present invention also provides the use of the aforementioned isopentenylphenolic compound I, and its pharmaceutically acceptable salt, in the preparation of a medicament for the prevention or treatment of type 2 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, or tumors.
[0063] In this invention, "room temperature" refers to 10-30℃.
[0064] The term "pharmaceutically acceptable salt" refers to a salt prepared from the compounds of the present invention with a relatively non-toxic, pharmaceutically acceptable acid or base. When the compounds of the present invention contain relatively acidic functional groups, a base addition salt can be obtained by contacting the prototype of such a compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. When the compounds of the present invention contain relatively basic functional groups, an acid addition salt can be obtained by contacting the prototype of such a compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent. The pharmaceutically acceptable acid includes inorganic or organic acids, which, when the compounds of the present invention contain relatively acidic or relatively basic functional groups, can be converted into base addition salts or acid addition salts. For details, see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977), or Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. HeinrichStahl and Camille G. Wermuth, ed., Wiley-VCH, 2002).
[0065] The term “treatment” refers to a therapeutic approach. When a specific condition is involved, treatment means: (1) alleviating one or more biological manifestations of the disease or condition; (2) interfering with (a) one or more points in a biological cascade that causes or induces the condition or (b) one or more biological manifestations of the condition; (3) improving one or more symptoms, effects or side effects associated with the condition, or one or more symptoms, effects or side effects associated with the condition or its treatment; or (4) slowing the development of the condition or one or more biological manifestations of the condition.
[0066] Without violating common sense in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.
[0067] The reagents and raw materials used in this invention are all commercially available.
[0068] The positive and progressive effects of this invention are as follows: This invention discovers an isopentenylphenolic compound as shown in Formula I, which has a strong affinity for PPARγ, can significantly reduce the glucose content in the cell lysate of insulin resistance model cells and increase the level of adiponectin, while having no obvious effect on promoting adipocyte differentiation and having few side effects. Attached Figure Description
[0069] Figure 1 The HSQC spectrum (acetone-d6, 600MHz) of isopentenylphenolic compound I prepared in Example 1 is shown.
[0070] Figure 2 The HMBC spectrum (acetone-d6, 600MHz) of isopentenylphenolic compound I prepared in Example 1 is shown.
[0071] Figure 3 ECD spectrum of isopentenylphenolic compound I prepared in Example 1 (JASCO Corp., J-810. Solvent used: chromatographic grade acetonitrile; test concentration: 0.02 mg / mL). Detailed Implementation
[0072] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.
[0073] Example 1: Preparation of isopentenylphenolic compound I
[0074] 1. Extraction: Take the dried black mulberry (Morus nigra L.) stem and branch coarse powder, add 90% ethanol, heat and reflux for extraction. The amount of 90% ethanol used is 8 (v / m, L / kg) times the amount of medicinal material. Extract twice, 1 hour each time. Filter the extract, combine and concentrate to obtain the extract.
[0075] 2. Column Chromatography: The extract was suspended in 10 times its weight of water and subjected to AB-8 macroporous resin column chromatography, eluting with water, 40% ethanol, and 95% ethanol, respectively, with each eluent used in 5 column volumes. The eluent obtained from the 95% ethanol elution was concentrated and dried, and then subjected to silica gel column chromatography, using gradient elution with petroleum ether:ethyl acetate (10:1, 7:1, 5:1, 2:1, 1:1, 2:3) solutions, with each gradient using 3 column volumes of mixed solvent. The fractions were identified by silica gel thin-layer chromatography, and those with the same Rf value were combined, resulting in a total of 23 fractions.
[0076] The 10th fraction (i.e., the eluent collected when the eluent volume is 10 times the column volume, or the eluent collected when the mixed solvent (petroleum ether: ethyl acetate = 2:1) volume is 1 times the column volume) was collected and analyzed by silica gel thin-layer chromatography. With dichloromethane:methanol = 12:1 as the developing solvent, the Rf value was 0.40. After concentration under reduced pressure, the eluent was further analyzed by gel column chromatography (hydroxypropyl dextran gel LH-20 (Sephadex LH-20), GE Healthcare Bio-Sciences). AB, Uppsala, and Sweden) chromatography was performed using dichloromethane:methanol at a 1:1 ratio. Fractions were collected sequentially in 15 mL tubes and identified by silica gel thin-layer chromatography. Fractions with the same Rf value were combined, resulting in a total of 7 fractions. The 6th fraction was collected (detected by silica gel thin-layer chromatography with dichloromethane:methanol = 12:1 as the developing solvent, Rf value 0.40). After concentration and drying, the fractions were subjected to reversed-phase silica gel ODS-C18 (ODS-A-HG, YMC) chromatography. (Co., Ltd., Japan) Chromatography was performed using gradient elution with methanol and water (40:60, 50:50, 60:40, 70:30, 80:20, 90:10), with each gradient using a mixed solvent volume of 2 column volumes. Each fraction was collected sequentially and identified by silica gel thin-layer chromatography. Fractions with the same Rf value were combined, resulting in a total of 15 fractions. The 9th fraction (i.e., the eluent collected when the mixed solvent (methanol:water = 80:20) was 10 column volumes) was collected and analyzed by silica gel thin-layer chromatography. When the developing solvent was dichloromethane:methanol = 12:1, the Rf value was 0.40. After concentration and drying, crude isopentenylphenolic compound I was obtained.
[0077] 3. HPLC preparation: The crude product of the above-mentioned isopentenylphenolic compound I was purified by HPLC to obtain isopentenylphenolic compound I: (5aR,10aS)-1,3,8,10a-tetrahydroxy-4-(2-hydroxy-3-methyl-3-buten-1-yl)-5a-(3-methyl-2-buten-1-yl)-5a,10a-dihydro-11H-benzofuran[3,2-b]chromogenone-11-one, with a retention time of 23.7 min.
[0078] The chromatographic conditions for HPLC are as follows:
[0079] Column type: Agilent Eclipse XDB-C 18 (250×10mm, 5μm)
[0080] Injection volume: 200 μL
[0081] Column temperature: room temperature,
[0082] Stationary phase: C18 bonded silicone,
[0083] Mobile phase and its volume ratio: Acetonitrile:water = 63:37
[0084] Detection wavelength: 210nm
[0085] Flow rate: 3 mL / min
[0086] Preparative liquid chromatography: LC3050N high performance liquid chromatograph.
[0087] Example 2: Structural identification of isopentenylphenolic compound I
[0088] Compound I: Yellow oil (methanol); (c 1.06,MeOH); HR-ESI-MS m / z453.1557[M–H] – (Calculated value 453.1549, C) 25 H 25 O8); UV(MeOH)λmax(logε)309(2.96); CD(MeOH)λmax(Δε)217(+7.45),238(-1.26),250(+1.53),274(-1.61),293(+2.37),331(+1.34)nm; IR(KBr)ν max (cm -1 ):3359,2927,1635,1649,1343,1262,1199,1148,1096; 1 H-NMR (600MHz, (CD3)2CO) and 13 C-NMR (150MHz, (CD3)2CO) data are shown in Table 1.
[0089] The quasi-molecular ion peak [M–H] given by HRESIMS spectroscopy. – With m / z 453.1557, the molecular formula of this compound is C2. 25 H 26O8, unsaturation degree 13; IR spectrum at 3359, 2927, 1635, 1459, 1148 cm⁻¹ -1 The presence of absorption indicates the presence of a benzene ring, carbonyl group, and double bond in the compound; the maximum UV absorption at 309 nm suggests that the compound is a mulberry root flavonoid.
[0090] 1 The H-NMR spectrum yielded the following signal: the characteristic C-5 hydrogen-bonded hydroxyl signal of flavonoids, δ H 11.70 (1H, br s, OH-5); A set of aromatic proton signals δ in the ABX system H 7.35 (1H, d, J = 8.0 Hz, H-6'), 6.50 (1H, dd, J = 8.0, 2.0 Hz, H-5'), and 6.37 (1H, d, J = 2.0 Hz, H-3'); a single-peak aromatic proton signal δ H 5.92 (1H, s, H-6); a set of 3-methyl-2-butenyl signals δ H 5.35 (1H, br t, J = 6.4 Hz, H-10), 3.10 (1H, br dd, J = 14.4, 8.0 Hz, H-9a), 2.76 (1H, br dd, J = 14.4, 7.6 Hz, H-9b), 1.60 (3H, br s, H-13) and 1.59 (3H, br s, H-12); a set of 2-hydroxy-3-methyl-3-butenyl signals δ H 4.84(1H,br s,H-17a),4.64(1H,br s,H-17b),4.30(1H,br dd,J=7.6,3.6Hz,H-15),2.90(1H,br dd,J=14.4,3.6Hz,H-14a),2.80(1H,br dd,J=14.4,7.6Hz,H-14b) and 1.64(3H,br s,H-18).
[0091] 13 The C-NMR spectrum showed 25 carbon signals, including 15 flavonoid skeleton carbon signals, of which δ C 91.5 (C-2) and δ C 102.8 (C-3) further confirms that the compound is a mulberry root flavonoid component; the 5-carbon signal of the 3-methyl-2-butenyl group, δ C 136.5 (C-11), δ C 118.6 (C-10), δ C 32.1(C-9), δ C25.9 (C-12) and 18.1 (C-13), and the five carbon signals of 3-hydroxy-2-methylbutenyl, δ C 148.3 (C-16), δ C 110.3(C-17), δ C 76.1(C-15), δ C 29.3 (C-14) and 18.2 (C-18).
[0092] Determining the carbon signal of hydrogen linkage using HSQC spectroscopy ( Figure 1 In the HMBC spectrum ( Figure 2 The correlations between H2-9a and C-2, C-10, and C-11, and between H-9a and C-3, confirm that the 3-methyl-2-butenyl group is attached at the C-2 position. The correlations between H2-17 and C-15, C-16, and C-18, and between H2-14 and C-15 and C-16, confirm the attachment of the 2-hydroxy-3-methyl-3-butenyl group. The correlations between H2-14 and C-8, C-8a, and C-7 confirm that this group is attached at the C-8 position. Further analysis of the HMBC spectrum, showing correlations between H-6 and C-7 and C-5, H-6' and C-2' and C-4', and H-3' and C-1', determined the chemical shifts of all carbon and hydrogen atoms. The planar structure of this compound was thus determined.
[0093] In the ECD spectrum of the compound ( Figure 3The compound exhibits a positive Cotton effect at 217, 250, 293, and 333 nm, and a negative Cotton effect at 238 and 276 nm. Based on the circular dichroism chromatographic rules of mulberry root flavonoids and through literature comparison (Hu X, Wu JW, Zhang XD, et al. Isoprenylated flavonoids and adipogenesis-promoting constituents from Morus nigra[J]. Journal of Natural Products, 2011, 74(4): 816-824; Shi YQ, Fukai T, Ochiai M. Absolute structures of 3-hydroxy-2-prenylflavanones with an ether linkage between the 2′- and 3-positions from moraceous plants[J]. Heterocycles, 2001, 55(1): 13-20), the absolute configurations of the C-2 and C-3 positions of this compound were determined to be 2R and 3S, respectively. Therefore, compound I was identified as (5aR,10aS)-1,3,8,10a-tetrahydroxy-4-(2-hydroxy-3-methyl-3-buten-1-yl)-5a-(3-methyl-2-buten-1-yl)-5a,10a-dihydro-11H-benzofuran[3,2-b]chromogenone-11-one.
[0094]
[0095] Table 1. Proton and carbon spectral data of compound I
[0096]
[0097]
[0098] Example 3: Study on the insulin sensitizing effect of isopentenylphenolic compound I
[0099] 3.1 Instruments
[0100] Microplate reader: BioTek, EPOCH; CO2 incubator (Thermo 3111), microscope (Olympus CX23), laminar flow hood (Suxin YJ-840 / YJ-1340), pipette (Eppendorff).
[0101] 3.2 Materials
[0102] 3T3-L1 cells: mouse preadipocytes, derived from the Chinese Academy of Sciences Cell Bank; DMEM (Gibco, C11995500CP); fetal bovine serum (Gibco, 2110875CP); Antibiotic-Antimycotic (Lifetechnologies, 15240-112); PBS, pH 7.4 (Gibco, 10010-500BT); Trypsin-EDTA (0.25%) (Gibco, 25200-056); IBMX (Sigma, I7018); Dexamethasone (Sigma, D4902); Insulin (Lifetechnologies, 12585-014); Induction culture medium: 1X standard culture medium; 0.5mM IBMX; 1μM Dexamethasone; 2μg / mL Insulin; stored at 4℃ for later use. Dexamethasone stock: 25 mg DEX dissolved in 1 mL anhydrous ethanol (MW = 392.46 g / mol) to make a 64 μM stock solution, store at 4°C for later use. IBMX stock: 110 mg IBMX dissolved in 1 mL DMSO (MW = 222.2 g / mol), aliquoted, store at -20°C for later use. Mouse Adiponectin ELISA Kit: Beyotime, PA002. Cell culture dishes: Coning, 430167; Cell culture flasks: Corning, 430639; Cell culture plates: Costa, 3596, 3599; Glucose test kit: Nanjing Jiancheng, F006-1-1.
[0103] SGF(Sanggenol F, The preparation method was prepared in the laboratory, referring to the literature: Xu Liangjin. Study on chemical composition and bioactivity of two ethnic medicinal plants [D]. Shanghai: China Pharmaceutical Industry Research Institute, 2018.
[0104] 3.3 Experimental Procedure
[0105] 3.3.1 Cell Culture
[0106] Mouse preadipocytes 3T3-L1 were routinely cultured in DMEM medium containing 10% FBS (containing 1X antibiotics).
[0107] 3.3.2 Induced Differentiation
[0108] Day 0: Replace the regular culture medium with induction culture medium (containing DEME, 0.5mM IBMX, 1μM dexamethasone, 2μg / mL insulin and 10% FBS), and incubate for 48h;
[0109] Day 2: Collect cells and replace the induction culture medium with insulin-containing culture medium (DMEM containing 10 μg / mL insulin and 10% FBS), and culture for 48 h;
[0110] Day 4: Change to DMEM culture medium containing 10% FBS, and change the medium every 48 hours.
[0111] Days 8-10: Over 90% of cells can differentiate and mature within 8-10 days.
[0112] 3.3.3 Preliminary investigation of the compound's cytotoxicity
[0113] Mature mouse 3T3-L1 cells were induced to differentiate and were seeded at a rate of 10,000 cells / 100 μl / well in 96-well plates after counting. 90 μl of culture medium (containing serum) was added to each well and the cells were cultured overnight, followed by the addition of 10 μl of the compound solution. After 48 h of culture, 100 μl of CTG was added to each well, and the cells were incubated at room temperature for 10 min. The chemiluminescence values of each well were measured using a microplate reader to calculate cell viability at the corresponding concentrations of each compound.
[0114] 3.3.4 Construction and Experimental Grouping of Insulin-Resistant Adipocytes
[0115] Mice 3T3-L1 adipocytes induced to differentiate into mature cells were randomly divided into a control group (Control), an insulin-resistant group (Model), and a drug-treated group. The Control group was cultured in high-glucose DMEM medium containing 10% FBS (containing 1% antibiotic), while the Model group was cultured in high-glucose DMEM medium containing 1 μM dexamethasone (containing 10% FBS and 1% antibiotic) for 96 h. The drug-treated groups received the same model treatment plus different concentrations of the drug and were cultured for 48 h. All groups were further divided into those without insulin and those treated with 1 nmol / L insulin. Glucose and adiponectin levels were measured after 48 hours. Rosiglitazone was used as a positive control. Glucose content in the supernatant was detected using the glucose oxidase-peroxidase method (GOD–POD) according to the kit instructions; adiponectin content in the cells was measured by ELISA.
[0116] 3.3.5 Statistical Analysis:
[0117] Statistical analysis was performed using Graphpad Prism 5.0 software. Results are expressed as mean ± standard deviation (x ± s). The t-test was used to compare the means between the two groups, with a significance level of α = 0.05.
[0118] 3.3.6 Activity Results
[0119] Compound I showed no significant toxicity to cells at 30 μM, with cell viability remaining at approximately 85%. Therefore, concentrations of 30 μM and 10 μM were selected for investigation. As shown in Tables 2 and 3, when 3T3-L1 adipocytes exhibited insulin resistance, the glucose content in the cell sap of the model group significantly increased under both basal and insulin-stimulated conditions; adiponectin content significantly decreased. Rosiglitazone, a positive control agent, significantly promoted glucose uptake and adiponectin secretion in insulin-resistant model cells at both 1.0 and 10.0 μM concentrations. Compound I significantly reduced glucose content in the cell sap at both 10.0 and 30.0 μM concentrations; at a high concentration (30 μM), it significantly increased adiponectin content in the cell sap, superior to SGF.
[0120] Table 2. Effects of compounds on glucose uptake in insulin-resistant 3T3-L1 adipocytes (n=3, )
[0121]
[0122]
[0123] Note: Rosiglitazone was used as a positive control. ## Compared with the control group, P < 0.01; * Compared with the insulin resistance group, P < 0.05; ** Compared with the insulin resistance group, P < 0.01
[0124] Table 3. Effect of compound I on adiponectin content in insulin-resistant adipocytes (n=3, )
[0125]
[0126] Note: ## Compared with the control group, P < 0.01; * Compared with the insulin resistance group, P < 0.05; ** Compared with the insulin resistance group, P < 0.01.
[0127] Example 4: Investigation of the adipocyte differentiation-promoting effect of isopentenylphenolic compound I
[0128] 4.1 Instruments
[0129] Inverted phase contrast microscope: Olympus
[0130] Other standard equipment includes: CO2 incubator, laminar flow hood, centrifuge, Eppendorf pipette, etc.
[0131] 4.2 Materials and Reagents
[0132] 3T3-L1: Mouse preadipocytes, derived from the Chinese Academy of Sciences Cell Bank; standard culture medium: DMEM; 10% FBS (Lifetechnologies, 10099); 1X Antibiotic-Antimycotic; stored at 4℃ for later use.
[0133] Induction culture medium: 1X conventional culture medium; 0.5mM IBMX; 1uM Dexamethasone; 2ug / mL Insulin; store at 4℃ for later use.
[0134] Dexamethasone stock: 25 mg DEX dissolved in 1 mL of anhydrous ethanol (MW = 392.46 g / mol) to form a 64 μM stock solution. Store at 4 °C for later use.
[0135] IBMX stock: 110mg IBMX dissolved in 1mL DMSO (MW=222.2g / mol), aliquoted, and stored at -20℃ for later use.
[0136] Oil Red O staining solution: Dissolve 5g of Oil Red O in 100mL of isopropanol, heat at 60℃ in the dark for 30min to dissolve, filter with filter paper to obtain 5g / L Oil Red O staining solution.
[0137] Oil Red O staining working solution: When ready to use, mix Oil Red O staining stock solution with distilled water in a ratio of 6:4 (V / V), cover and let stand for 30 minutes, carefully aspirate the supernatant and filter again with qualitative filter paper.
[0138] Other: DMEM (Lifetechnologies, 31966); FBS (Lifetechnologies, 10099); Antibiotic-Antimycotic (Lifetechnologies, 15240-112); IBMX (Sigma, I7018); Dexamethasone (Sigma, D4902); Insulin (Lifetechnologies, 12585-014); PBS, pH 7.4 (Lifetechnologies, 10010-049); Oil Red O (Sigma, O9755); 4% Paraformaldehyde Fixative (Boster, AR1068)
[0139] 4.3 Experimental Procedure
[0140] 4.3.1 Differentiation of 3T3-L1 preadipocytes
[0141] 4.3.1.1 Cell Culture: Mouse preadipocytes 3T3-L1 were routinely cultured in DMEM medium containing 10% FBS (containing 1X antibiotics).
[0142] 4.3.1.2 Induction of Differentiation: After 3T3-L1 cells reached fusion, differentiation was induced according to the following protocol. The specific process is as follows:
[0143] 4.3.1.2.1 Day 0: Replace the regular culture medium with induction culture medium and incubate for 48 hours;
[0144] 4.3.1.2.2 Day 2: Collect cells and replace the induction culture medium with insulin-containing culture medium, and culture for 48 hours;
[0145] 4.3.1.2.3 Day 4: Change the culture medium to DMEM containing 10% FBS every 48 hours.
[0146] Different concentrations of the compound and the positive control rosiglitazone were added during the induction process. Oil red blood cell staining and lipid droplet aggregation were performed on day 7 after induction.
[0147] 4.3.2 Oil Red O fat staining:
[0148] 4.3.2.1 Discard a portion of the culture medium in the culture dish and wash three times with PBS;
[0149] 4.3.2.2 Fix with 4% paraformaldehyde for 20 min, then wash 3 times with PBS;
[0150] 4.3.2.3 After fixation, the cells were incubated with Oil Red O dilution at room temperature for 1 hour, rinsed with distilled water 3 times, and observed and photographed under a microscope;
[0151] 4.3.2.4 A portion was dissolved in isopropanol and then measured for OD490nm using an ELISA reader;
[0152] 4.4 Experimental Results: As shown in Table 4, compound I had no significant adipocyte differentiation effect at a concentration of 10 μM, and at a concentration of 30 μM, the adipocyte differentiation promotion rate was 3.72%, which was much weaker than SGF and rosiglitazone (1 μM).
[0153] Table 4. The promoting effect of compound I on adipocyte differentiation.
[0154]
[0155] Example 5: PPARγ affinity test of isopentenylphenolic compound I
[0156] 5.1 Experimental Apparatus
[0157] PerkinElmer EPOCH microplate reader, pipettes (Eppendorff), liquid handling system: Echo 555 (Labcyte), etc.
[0158] 5.2 Experimental Materials
[0159] LanthaScreen TM TR-FRET PPARγ Competitive Binding Assay Kit (Invitrogen-PV4894); DTT (Invitrogen-P2325)
[0160] 5.3 Experimental Procedure
[0161] According to LanthaScreen TM The experiment was conducted according to the instructions of the TR-FRET PPARγ competitive binding assay kit.
[0162] ① Transfer 200 nm of different concentrations of the compound and the control GW1929 to an Echo plate using an Echo plate. Simultaneously, transfer 200 nm of DMSO as a high control (HC) and 200 nm of GW1929 containing 1000 nM as a low control. Centrifuge for 1 min, add 20 μL of buffer, and centrifuge for another 1 min.
[0163] ② Add 10 μL of the prepared 4X PPARγ-LBD / Tb-anti-GST Ab (containing 0.6 nM PPARγ-LBD and 0.21 nM Tb-anti-GST Ab, and incubate in the dark at 4°C for 60 min) to each well, centrifuge for 1 min, and then incubate at room temperature for 30 min.
[0164] ③ Add 10 μL of 4× Fluormone TM Pan-PPAR Green, centrifuged for 1 min, incubated at room temperature for 1 h.
[0165] TR-FRET signals were detected using an EnVision flatbed reader. Fluorescence intensity in each well was measured (donor fluorescence 495 nm, acceptor fluorescence 520 nm), and the TR-FRET ratio (Value, 520 nm fluorescence value / 495 nm fluorescence value) was calculated. The inhibition rates of different compound concentrations were obtained using the formula below, and dose-response curves were plotted using Graphpad Prism 5.0 software to calculate the IC50. 50 value.
[0166] Inhibition rate (%) = [1 - (Value)] 化合物 -Value 低对照 ) / (Value 高对照 -Value低对照 )]*100%
[0167] Calculate the binding constant K using the following formula. i value:
[0168]
[0169] Where [tracer] is the donor concentration corresponding to the maximum TR-FRET value in the detection reaction, which was set to 3 nM in this experiment; Kd is the binding constant of the donor fluorescence, and the Kd value in this experiment was 2.8 ± 0.8 nM; IC 50 The concentration of the analyte that corresponds to half of the maximum TR-FRET value.
[0170] 5.4 Experimental Results
[0171] As shown in Table 5, compound I exhibits good affinity for the PPARγ receptor, IC50... 50 The value is 5.10 μM, and the binding constant (K) i 2.46 μM; IC50 of the positive control rosiglitazone 50 The PPARγ receptor affinity of compound I was 104.8 nM and Ki was 50.6 nM, respectively; compound I had a better affinity for the SGF (ICP-γ receptor than SGF). 50 The values and Ki were 18.39 μM and 8.87 μM, respectively.
[0172] Table 5. Affinity test of compounds with PPARγ receptors (n=3)
[0173]
[0174] Note: Ki=IC 50 / (1+[tracer] / Kd),[tracer]=3nM,Kd=2.8nm
[0175] Example 6: PPARγ agonist activity of isopentenylphenolic compound I
[0176] 6.1 Experimental Apparatus
[0177] PerkinElmer EPOCH microplate reader, pipettes (Eppendorff), liquid handling system: Echo 555 (Labcyte), etc.
[0178] 6.2 Experimental Materials
[0179] HEK293 cells (American Type Culture Collection, Manassas, USA), plasmid vector pcDNA3.1, transfection reagent (Invitrogen); luciferase reporter gene plasmid, GAL4 DNA binding region (Gal4DB) expression plasmid, etc.
[0180] 6.3 Experimental Procedure
[0181] PPARγ agonist activity was evaluated using a dual-luciferase assay, with HEK293 cells as the test cells and rosiglitazone as the positive control. HEK293 cells were first cultured at 37°C with 5% CO2 / air for 24 hours. Then, 50 ng of a mixed plasmid of pBIND-PPARγ and pG5Luc was transfected into the cells using FuGENE HP transfection reagent. After 24 hours of incubation, different concentrations of the test sample were added to each well. Eight hours later, the firefly and renilla signals of each well were read using a multi-mode microplate reader. PPARγ agonist activity was expressed as the ratio of the fluorescence intensity of the sample system to that of the blank control, and the fluorescence intensity was expressed as the ratio of the firefly signal intensity to the renilla signal intensity.
[0182] 6.4 Experimental Results: As shown in Table 6, compounds I and SGF showed no significant agonist activity at 1 μM and some PPARγ agonist activity at 10 μM, but the percentages compared to the complete agonist rosiglitazone were 8.52% and 7.34%, respectively. This suggests that compounds I, like SGF, are partial agonists.
[0183] Table 6. PPARγ agonist activity of compounds (n=3)
[0184]
[0185] Note: *p<0.05 vs. DMSO, n=3, corresponding to rosiglitazone percentage (%) = (multiple) 样品 -multiple DMSO ) / (multiple 罗格列酮 -multiple DMSO )*100%
[0186] In summary, isopentenylphenol compound I exhibits significant insulin-sensitizing activity and no obvious prolipolysis-promoting effect, demonstrating superior activity and side effects compared to its counterpart, Sanggenol F. Furthermore, at a concentration of 30 μM, its insulin-sensitizing activity is comparable to that of the positive control drug rosiglitazone at 1 μM, but its side effects are significantly lower, indicating that this compound has potential development value.
Claims
1. An isopentenylphenolic compound I or a pharmaceutically acceptable salt thereof, 。 2. A process for the preparation of the isoprenyl phenolic compound I according to claim 1, characterized in that, It includes the following steps: ① The ethanol extract of black mulberry stems and branches was suspended in water and subjected to AB-8 macroporous resin column chromatography. The eluent was eluted with water, 40% ethanol and 95% ethanol respectively. The eluent obtained by elution with 95% ethanol was concentrated and dried to obtain mixture 1. ② Mixture 1 was subjected to silica gel column chromatography with gradient elution using a mixed solution of petroleum ether and ethyl acetate. The volume ratios of petroleum ether and ethyl acetate were 10:1, 7:1, 5:1, 2:1, 1:1, and 2:3, respectively. The eluent, which was analyzed by silica gel thin-layer chromatography and showed a dichloromethane and methanol volume ratio of 12:1 with an Rf value of 0.40, was collected, concentrated, and dried to obtain mixture 2. ③ The mixture 2 was subjected to gel column chromatography and eluted with dichloromethane and methanol in a volume ratio of 1:
1. The eluent was collected and analyzed by silica gel thin-layer chromatography. The eluent had a dichloromethane and methanol volume ratio of 12:1 and an Rf value of 0.
40. The eluent was then concentrated and dried to obtain mixture 3. ④ The mixture 3 was subjected to reversed-phase silica gel column chromatography with gradient elution of methanol and water. The volume ratio of methanol to water was 40:60, 50:50, 60:40, 70:30, 80:20, and 90:10, respectively. The eluent was collected and analyzed by silica gel thin-layer chromatography. When the volume ratio of dichloromethane to methanol was 12:1, the Rf value was 0.
40. After concentration, the crude product of isopentenylphenolic compound I was obtained. ⑤ The crude isopentenylphenolic compound I was purified by HPLC. The stationary phase of the HPLC column was C18 bonded silica gel, and the mobile phase was a mixed solution of acetonitrile and water; the volume ratio of acetonitrile to water was 63:
37.
3. The production method according to claim 2, wherein The preparation method described herein satisfies one or more of the following conditions: (1) Extract the coarse powder of black mulberry stems and branches with ethanol, and filter and concentrate the extract to obtain the black mulberry stem and branch ethanol extract. (2) In step ①, when the black mulberry stem and branch ethanol extract is suspended in water, the weight ratio of the black mulberry stem and branch ethanol extract to the water is 1:5~15. (3) In step ①, when performing AB-8 macroporous resin column chromatography, the amounts of water, 40% ethanol and 95% ethanol are 5 times the column volume, respectively. (4) In step ②, the amount of petroleum ether and ethyl acetate mixed solution used in each gradient is 3 times the column volume; (5) In step ③, the filler for the gel column is hydroxypropyl dextran gel LH-20; (6) In step ④, the packing material for the reversed silica gel column chromatography is ODS-C18; (7) In step ④, when performing gradient elution with methanol and water, the amount of mixed solvent used for each gradient is 3 times the column volume; (8) In step ⑤, the particle size of the packing material of the HPLC column is 5~10 μm; (9) In step ⑤, the length of the HPLC column is 100~250 mm; (10) In step ⑤, the inner diameter of the HPLC column is 9.4~30 mm; (11) In step ⑤, the column temperature of the HPLC column is 20~50℃; (12) In step ⑤, the detection wavelength of the HPLC is 200~400 nm; (13) In step ⑤, the flow rate of the mobile phase of the HPLC is 1~15 mL / min; (14) In step ⑤, the injection volume of the HPLC is 10~1000μL.
4. The production method according to claim 3, wherein The preparation method described herein satisfies one or more of the following conditions: (1) In the process of extracting the coarse powder of black mulberry stems and branches with ethanol, the ethanol is 90% ethanol; (2) During the extraction of the coarse powder from black mulberry stems and branches with ethanol, the extraction temperature is 80℃; (3) In the process of extracting the coarse powder of black mulberry stems and branches with ethanol, the volume-to-mass ratio of ethanol to the coarse powder of black mulberry stems and branches is 8 L / kg. (4) In the process of extracting the coarse powder of black mulberry stems and branches with ethanol, the extraction is performed twice. (5) During the extraction of the coarse powder from black mulberry stems and branches with ethanol, the extraction time is 1 hour. (6) In step ①, when the black mulberry stem and branch ethanol extract is suspended in water, the weight ratio of the black mulberry stem and branch ethanol extract to the water is 1:
10. (7) In step ④, the packing material for the reversed-phase silica gel column chromatography is ODS-A-HG; (8) In step ⑤, the HPLC column is an Agilent Eclipse XDB-C18, 250 × 10 mm, 5 μm; (9) In step ⑤, the column temperature of the HPLC column is room temperature; (10) In step ⑤, the detection wavelength of the HPLC is 210 nm; (11) In step ⑤, the flow rate of the mobile phase of the HPLC is 3 mL / min; (12) In step ⑤, the injection volume of the HPLC is 200 μL.
5. A pharmaceutical composition, characterized by, It includes: (1) The isopentenylphenolic compound I as described in claim 1, or a pharmaceutically acceptable salt thereof, and (2) At least one pharmaceutical excipient.
6. The use of isopentenylphenolic compound I as described in claim 1 or a pharmaceutically acceptable salt thereof in the preparation of an insulin sensitizer.
7. The use of the isopentenylphenolic compound I as described in claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a PPARγ partial agonist.
8. Use of the isopentenylphenolic compound I as described in claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the prevention or treatment of insulin resistance or metabolic diseases caused by insulin resistance.
9. The use of an isopentenylphenolic compound I as described in claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the prevention or treatment of type 2 diabetes, obesity, hypertension, hyperlipidemia or atherosclerosis.
